BiotechTube

alefacept

ApprovedTerminated
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Chronic Plaque Psoriasis

Conditions

Chronic Plaque Psoriasis

Trial Timeline

Feb 1, 2008 → Dec 1, 2008

NCT ID
NCT00953329

About alefacept

alefacept is a approved stage product being developed by Astellas Pharma for Chronic Plaque Psoriasis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00953329. Target conditions include Chronic Plaque Psoriasis.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Plaque Psoriasis were approved

Approved (20) Terminated (2) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅lysozyme 90 mg + PlaceboEisaiApproved
✅lorcaserin + phentermine placebo + lorcaserin + phentermine-HCl + phentermine placebo + lorcaserin + phentermine-HClEisaiApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (10)

NCT IDPhaseStatus
NCT01267643Phase 1Terminated
NCT01226420Phase 2Terminated
NCT00808223Phase 2Completed
NCT00815633ApprovedTerminated
NCT00953329ApprovedTerminated
NCT00832585ApprovedCompleted
NCT00658606ApprovedCompleted
NCT00168753ApprovedCompleted
NCT00674063Phase 3Completed
NCT00692172Phase 3Completed

Competing Products

20 competing products in Chronic Plaque Psoriasis

See all competitors
ProductCompanyStageHype Score
Levofloxacin 500Dr. Reddy's LaboratoriesPre-clinical
23
mRNA-0184ModernaPhase 1
0
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25